Multiple Myeloma

Amgen: Why No One Cares About Kyprolis Trial Failure
Amgen: Why No One Cares About Kyprolis Trial Failure
Barron's
Amgen
Kyprolis
Multiple Myeloma
Flag link:
Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a Big Deal
Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a Big Deal
Motley Fool
Amgen
Kyprolis
Multiple Myeloma
Flag link:
Amgen Drops in After Hours on Failed Trial, Recall
Amgen Drops in After Hours on Failed Trial, Recall
Barron's
Amgen
Kyprolis
recalls
Aranesp
Multiple Myeloma
Flag link:
Amgen reports positive trial of multiple myeloma treatment
Amgen reports positive trial of multiple myeloma treatment
Marketwatch
Amgen
Multiple Myeloma
Kyprolis
Flag link:
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
Pipeline Review
daratumumab
Multiple Myeloma
Flag link:
Will Amgen’s Acquisition of Onyx Pay off Soon?
Will Amgen’s Acquisition of Onyx Pay off Soon?
Motley Fool
M&A
Amgen
ONYX Pharmaceuticals
Kyprolis
Multiple Myeloma
Flag link:
Novartis bone marrow drug improves progression-free survival
Novartis bone marrow drug improves progression-free survival
Yahoo/Reuters
Novartis
LBH589
Multiple Myeloma
ASCO
Flag link:
Stemline's SL-401 significantly decreased the viability of malignant cells
Stemline's SL-401 significantly decreased the viability of malignant cells
The Fly on the Wall
Stemline Therapeutics
SL-401
Multiple Myeloma
Flag link:
Bristol-Myers, AbbVie granted breakthrough therapy designation for elotuzumab
Bristol-Myers, AbbVie granted breakthrough therapy designation for elotuzumab
The Fly on the Wall
Bristol-Myers Squibb
AbbVie
elotuzumab
Multiple Myeloma
Flag link:
Spectrum Pharma's cancer drug meets main goal in trial
Spectrum Pharma's cancer drug meets main goal in trial
Yahoo/Reuters
Spectrum Pharmaceuticals
melphalan
Multiple Myeloma
Flag link:
Novartis: 2 Novel Cancer Therapies Show Promising Results
Novartis: 2 Novel Cancer Therapies Show Promising Results
Seeking Alpha
Novartis
Celgene
JNJ
Merck
panobinostat
Multiple Myeloma
acute lymphocytic leukemia
Flag link:
Celgene advances after analysts say Revlimid data positive
Celgene advances after analysts say Revlimid data positive
The Fly on the Wall
Revlimid
Celgene
Multiple Myeloma
Flag link:
Novartis bone marrow cancer drug meets goal in late-stage study
Novartis bone marrow cancer drug meets goal in late-stage study
Yahoo/AP
Novartis
LBH589
Multiple Myeloma
Flag link:
Celgene's Revlimid Faces a Tough Sell
Celgene's Revlimid Faces a Tough Sell
Motley Fool
Celgene
Revlimid
JNJ
Multiple Myeloma
Flag link:
Has Myeloma Met Its Match in Amgen's Kyprolis?
Has Myeloma Met Its Match in Amgen's Kyprolis?
Motley Fool
Multiple Myeloma
Amgen
Kyprolis
Celgene
Flag link:
Celgene's Revlimid Makes Stronger Case for European Front-Line Approval
Celgene's Revlimid Makes Stronger Case for European Front-Line Approval
TheStreet.com
Celgene
Revlimid
Europe
Multiple Myeloma
Flag link:
J&J's Velcade gets stiff-armed at NICE as first-line myeloma treatment
J&J's Velcade gets stiff-armed at NICE as first-line myeloma treatment
Fierce Pharma
JNJ
Velcade
Multiple Myeloma
Flag link:
Array Biopharma Outlines Path To Market For New Myeloma Drug
Array Biopharma Outlines Path To Market For New Myeloma Drug
Forbes
Multiple Myeloma
Array Biopharma
ARRY-520
Kyprolis
Flag link:
Celgene's New Multiple Myeloma Drug Is Beating Amgen
Celgene's New Multiple Myeloma Drug Is Beating Amgen
TheStreet.com
Celgene
Multiple Myeloma
Amgen
Kyprolis
Pomalyst
Flag link:
Celgene says phase III study of pomalidomide combo met primary endpoint
Celgene says phase III study of pomalidomide combo met primary endpoint
Yahoo/Fly on the Wall
Celgene
pomalidomide
Multiple Myeloma
Flag link:

Pages